Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Novartis
Novartis
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Adicet Therapeutics
Genmab
Genmab
Genmab
Genmab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Genmab
Genmab
Hoffmann-La Roche
Seagen Inc.
Incyte Corporation
Pfizer
City of Hope Medical Center
Acerta Pharma BV
Pfizer
ADC Therapeutics S.A.
Ohio State University Comprehensive Cancer Center
Fred Hutchinson Cancer Center
Cellectar Biosciences, Inc.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Seagen Inc.
Galapagos NV
BeOne Medicines
M.D. Anderson Cancer Center
Dizal Pharmaceuticals
Monte Rosa Therapeutics, Inc
Merck Sharp & Dohme LLC
Tanabe Pharma Corporation
Hoffmann-La Roche
Ohio State University Comprehensive Cancer Center
IRCCS San Raffaele
Regeneron Pharmaceuticals
Mayo Clinic
Hoffmann-La Roche
Alliance for Clinical Trials in Oncology
University of Wisconsin, Madison
H. Lee Moffitt Cancer Center and Research Institute
Massachusetts General Hospital
City of Hope Medical Center
Roswell Park Cancer Institute
University of Michigan Rogel Cancer Center
Memorial Sloan Kettering Cancer Center
Incyte Corporation
Dana-Farber Cancer Institute
Fred Hutchinson Cancer Center
Centre Henri Becquerel